The KO result provides clear experimental evidence that single GLUT targeting may not be effective and pan-GLUT targeting, as demonstrated by our DRB18 tumor study (Fig. 5a–c) is likely to be an alternative and better route for developing a new effective anticancer therapeutic strategy. This evidence concerns the gene SLC2A1 and neoplasm.